Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Expanded Access
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Institutional experience with
nab
-sirolimus in patients with malignancies harboring
TSC1
or
TSC2
mutations
Home
Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations
Next Post
Previous Post
Institutional experience with
nab
-sirolimus in patients with malignancies harboring
TSC1
or
TSC2
mutations
June 4, 2021
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Evaluation of
nab
-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1
Aadi Bioscience Closes $23 Million in Series A Funding
Read More
Emma Reeve
nab
-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.